A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.

Creatine supplementation showed mixed effects on depressive symptoms across five randomized trials involving patients with mood disorders. The early findings suggest potential adjunctive benefit in some populations but do not establish a consistent treatment effect.

Primary care physicians increasingly inherit adult ADHD stimulant prescriptions amid specialist shortages and medication supply disruptions. Expert guidance highlights diagnostic verification, monitoring, and risk-assessment considerations without establishing a single standardized approach.

Youth with ADHD and comorbid ASD showed distinct medication patterns and greater psychiatric burden in a large EHR cohort. The observational findings did not establish causal treatment effects.

Short-term benzodiazepine use after mass trauma was not associated with increased 12-month PTSD risk in a large retrospective cohort. Persistent use showed a different pattern, and the observational findings did not establish causality.

FcγRIII-mediated macrophage phagocytosis emerges as the dominant mechanism of platelet destruction in FNAIT, suggesting targeted receptor blockade could offer a future therapeutic approach, though evidence remains preclinical.